Supplementary Figures and Tables from Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma

Supplementary Table 1. Dose-response effects of human glioblastoma cells after treatment with NG34 or rQNestin34.5. Supplementary Figure S1. A, The dose-response curves represent cell viability assay for human astrocytes. Intracellular ATP was measured as an index of cell viability, five days after infection of human astrocyte cells with NG34 or rQNestin34.5. Data were normalized to maximum and minimum values before plotting the averaged values of six replicates with S.D. error bars and non-linear dose-response curves. Ranges of 50% effective doses (ED50) at 95% confidence intervals are 0.00094-0.0034 pfu (NG34) and 0.0011-0.0024 puf (rQNestin34.5), and values of R2 are 0.9423 (NG34) and 0.9748 (rQNestin34.5), respectively. B, viral replication in normal tissues was measured by titrating viral yields collected from cultured human astrocytes after HSV1 F strain (wild-type), rHSVQ, NG34 or rQNestin34.5 at 0.1 of their MOIs. Error bars represent S.D (n = 4). Supplementary Figure S2. The dose-response curves represent are obtained from the cell viability assay used in Table. 1. Supplementary Figure S3. NG34-gCRliFluc and rHSVQ-gCRliFluc oHSV were generated as described in the Materials and Methods section . Supplementary Figure S4. Bioluminescent imaging of xenografted human glioma indicates tumor regression upon oHSV treatment. Supplementary Figure S5. Reproducibility of therapeutic efficacy of NG34 in different models in vivo. Supplementary Figure S6. Gene expression of cytokines in mouse brains with NG34 inoculation. Supplementary Figure S7. Immunohistochemistry of the brains of athymic mice after the HSV-1 inoculation.